Boryung Past Earnings Performance
Past criteria checks 5/6
Boryung has been growing earnings at an average annual rate of 11.3%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 13.2% per year. Boryung's return on equity is 10.9%, and it has net margins of 7%.
Key information
11.3%
Earnings growth rate
7.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 13.2% |
| Return on equity | 10.9% |
| Net Margin | 7.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
We Think Boryung (KRX:003850) Is Taking Some Risk With Its Debt
Sep 20
Earnings Not Telling The Story For Boryung Corporation (KRX:003850)
Aug 05Why We're Not Concerned About Boryung Corporation's (KRX:003850) Share Price
Apr 06A Look At The Fair Value Of Boryung Pharmaceutical Co., Ltd. (KRX:003850)
Apr 28Boryung Pharmaceutical (KRX:003850) Has A Pretty Healthy Balance Sheet
Mar 17Here's How We Evaluate Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Dividend
Feb 27Is Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Feb 09Do Institutions Own Boryung Pharmaceutical Co., Ltd. (KRX:003850) Shares?
Jan 25Should You Use Boryung Pharmaceutical's (KRX:003850) Statutory Earnings To Analyse It?
Jan 10
If You Had Bought Boryung Pharmaceutical (KRX:003850) Shares Three Years Ago You'd Have Earned 122% Returns
Dec 23Is Boryung Pharmaceutical (KRX:003850) A Risky Investment?
Dec 08Would Boryung Pharmaceutical Co., Ltd. (KRX:003850) Be Valuable To Income Investors?
Nov 23Revenue & Expenses Breakdown
How Boryung makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 928,718 | 64,579 | 223,422 | 52,073 |
| 31 Mar 24 | 889,416 | 52,254 | 220,641 | 50,585 |
| 31 Dec 23 | 859,626 | 40,203 | 214,854 | 47,286 |
| 30 Sep 23 | 829,854 | 28,267 | 201,656 | 41,603 |
| 30 Jun 23 | 819,463 | 38,284 | 200,154 | 41,415 |
| 31 Mar 23 | 785,679 | 42,063 | 195,427 | 40,249 |
| 31 Dec 22 | 760,476 | 41,894 | 191,858 | 41,705 |
| 30 Sep 22 | 724,659 | 53,911 | 184,422 | 43,444 |
| 30 Jun 22 | 694,170 | 52,524 | 178,676 | 41,373 |
| 31 Mar 22 | 661,948 | 34,380 | 173,972 | 40,604 |
| 31 Dec 21 | 627,279 | 43,044 | 171,818 | 39,146 |
| 30 Sep 21 | 600,008 | 41,823 | 167,985 | 36,053 |
| 30 Jun 21 | 587,350 | 28,892 | 167,011 | 35,884 |
| 31 Mar 21 | 571,594 | 38,370 | 159,083 | 36,957 |
| 31 Dec 20 | 561,867 | 26,856 | 148,224 | 35,506 |
| 30 Sep 20 | 562,433 | 27,744 | 144,704 | 36,253 |
| 30 Jun 20 | 546,974 | 27,969 | 140,383 | 39,247 |
| 31 Mar 20 | 539,742 | 31,678 | 140,141 | 36,934 |
| 31 Dec 19 | 524,269 | 32,222 | 139,544 | 37,864 |
| 30 Sep 19 | 498,006 | 32,950 | 127,560 | 36,683 |
| 30 Jun 19 | 480,242 | 29,886 | 124,855 | 34,458 |
| 31 Mar 19 | 467,445 | 22,830 | 125,221 | 35,580 |
| 31 Dec 18 | 460,402 | 20,307 | 122,204 | 34,433 |
| 30 Sep 18 | 441,580 | 64,630 | 107,695 | 58,302 |
| 30 Jun 18 | 440,087 | 62,855 | 115,359 | 49,298 |
| 31 Mar 18 | 434,565 | 60,451 | 127,963 | 32,997 |
| 31 Dec 17 | 422,721 | 56,699 | 127,666 | 32,277 |
| 30 Sep 17 | 426,554 | -3,202 | 145,023 | 7,366 |
| 30 Jun 17 | 423,777 | -2,977 | 137,328 | 14,638 |
| 31 Mar 17 | 420,133 | 5,020 | 120,819 | 29,164 |
| 31 Dec 16 | 409,140 | 5,614 | 121,778 | 28,963 |
Quality Earnings: A003850 has high quality earnings.
Growing Profit Margin: A003850's current net profit margins (7%) are higher than last year (4.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A003850's earnings have grown by 11.3% per year over the past 5 years.
Accelerating Growth: A003850's earnings growth over the past year (68.7%) exceeds its 5-year average (11.3% per year).
Earnings vs Industry: A003850 earnings growth over the past year (68.7%) exceeded the Pharmaceuticals industry 21.9%.
Return on Equity
High ROE: A003850's Return on Equity (10.9%) is considered low.